Abstract
Prolymphocytic leukemia was originally described as a variant of chronic lymphocytic leukemia. B-prolymphocytic and T-prolymphocytic leukemia have similar morphology and some clinic, but their biology and pathology differs; both diseases are rare, corresponding to approximately 2% of chronic lymphocytic leukemias, approx. 80% have B-phenotype.
WHO classification designates specific diagnostic criteria. Modern therapy includes mostly purine analogs and monoclonal antibodies antiCD52and antiCD20.
Despite the progress in the therapy the prognosis of patients is poor and the median survival by most of patients is only couple of months.